{"id":"tamoxifen-aminoglutethimide","safety":{"commonSideEffects":[{"rate":"null","effect":"Hot flashes"},{"rate":"null","effect":"Vaginal discharge"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Vomiting"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tamoxifen's SERM activity blocks estrogen receptors in breast tissue, which can help slow or stop the growth of hormone receptor-positive breast cancer cells. Aminoglutethimide's inhibition of CYP11A1 reduces the production of estrogen, which can also slow the growth of hormone receptor-positive breast cancer cells.","oneSentence":"Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action in breast tissue, while aminoglutethimide inhibits the enzyme CYP11A1, which is involved in the synthesis of steroids, including estrogen.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:37:31.680Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease"}]},"trialDetails":[{"nctId":"NCT00309491","phase":"PHASE3","title":"Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1990-12","conditions":"Early-stage Breast Cancer","enrollment":2021}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nolvadex + Orimeten"],"phase":"phase_3","status":"active","brandName":"Tamoxifen + Aminoglutethimide","genericName":"Tamoxifen + Aminoglutethimide","companyName":"Austrian Breast & Colorectal Cancer Study Group","companyId":"austrian-breast-colorectal-cancer-study-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action in breast tissue, while aminoglutethimide inhibits the enzyme CYP11A1, which is involved in the synthesis of steroids, including estrogen. Used for Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}